Skip to main content
. 2014 Dec 18;112(1):E21–E29. doi: 10.1073/pnas.1417015112

Fig. 6.

Fig. 6.

Dual inhibition of GLS and Hsp90 causes a regression of xenograft tumor development. (A) Female CB17-scid mice were inoculated with ELT3-luciferase cells s.c. Mice were treated with vehicle, BPTES, 17AAG, or combined BPTES and 17AAG for 3 wk. Body weight was measured every week. (B) Tumor area was measured weekly by using a digital caliper. The left y axis indicates the relative fold growth of tumor size vs. the baseline measurement before drug treatment. (C and D) Bioluminescent intensity in xenograft tumors was recorded and quantified weekly. The left y axis indicates the relative tumor growth vs. the baseline quantification before drug treatment. (E) Representative images of immunohistochemical staining of cell proliferation marker PCNA in tumors from mice treated with vehicle, BPTES, 17AAG, or combined BPTES and 17AAG. Percentage of cells with nuclear immunoreactivity of PCNA was scored from four to six random fields per section. **P < 0.01, Student t test. (F) Representative images of tumor sections labeled by TUNEL, a method for detecting apoptotic cell death, in tumors from mice treated vehicle, BPTES, 17AAG, or BPTES plus 17AAG.